CM
ACAD icon

Castleark Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Castleark Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-96,045
Closed -$4.66M – 344
2020
Q2 		$4.66M Sell
96,045
-117,025
-55% -$5.62M 0.2% 129
2020
Q1 		$9M Sell
213,070
-2,700
-1% -$111K 0.53% 52
2019
Q4 		$9.23M Buy
215,770
+23,700
+12% +$1.03M 0.37% 88
2019
Q3 		$6.91M Buy
+192,070
New +$5.82M 0.28% 126
2017
Q2 		– Sell
-206,980
Closed -$7.12M – 389
2017
Q1 		$7.12M Buy
+206,980
New +$7.31M 0.22% 149

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.6B AUM 47.77% 1-Year Est. Return